Art. -Nr.: HY-117275

Meclofenamic acid

(Synonyms: Meclofenamate)

9 Cited Publications

Kundenbewertung

Based on 9 publication(s) in Google Scholar

Meclofenamic acid (Meclofenamate) is a non-steroidal anti-inflammatory agent. Meclofenamic acid is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker. Meclofenamic acid inhibits hKv2.1 and hKv1.1, with IC₅₀ values of 56.0 and 155.9 μM, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.66%
CAS. Nr.: 644-62-2
Formel: C₁₄H₁₁Cl₂NO₂
Molecular Weight:296.15

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Meclofenamic acid Chemical Structure

CAS. Nr.: 644-62-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (9)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 1 μM (cyclooxygenase), 56.0 μM (hKv2.1), 155.9 μM (hKv1.1)^[3]

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
RBL-1	IC₅₀	0.1 μM Compound: 1a	Inhibition of Prostaglandin G/H synthase mediated PGF2-alpha formation in rat basophilic leukemia (RBL-1) cells Inhibition of Prostaglandin G/H synthase mediated PGF2-alpha formation in rat basophilic leukemia (RBL-1) cells	[PMID: 8515419]
RBL-1	IC₅₀	0.1 μM Compound: 1a (Meclofenamic acid)	Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-Cyclooxygenase Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-Cyclooxygenase	10.1016/S0960-894X(00)80657-5
RBL-1	IC₅₀	24 μM Compound: 1a	Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells	[PMID: 8515419]
RBL-1	IC₅₀	24 μM Compound: 1a (Meclofenamic acid)	Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase	10.1016/S0960-894X(00)80657-5

In Vitro

Meclofenamic acid (0-100 μM, 24 h) inhibits FTO demethylation in a dose-response manner^[1].
Meclofenamic acid inhibits enzyme cyclooxygenase, with an IC₅₀ about 1 μM, thereby inhibiting the production of prostaglandins^[2].
Meclofenamic acid inhibits the release of 5-HETE and LTB4 from human neutrophils stimulated with calcium ionophore and antagonizes the response of tissues to certain prostaglandins^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

HeLa cells
Concentration:

0, 12.5, 25, 50, 100 μM
Incubation Time:

24 h
Result:

Inhibited FTO demethylation in a dose-response manner, and elevates the levels of cellular m6A in mRNA by targeting FTO.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 644-62-2
Appearance Solid
Molecular Weight 296.15
Formel C₁₄H₁₁Cl₂NO₂
Color White to yellow
SMILES

O=C(O)C1=CC=CC=C1NC2=C(Cl)C=CC(C)=C2Cl
Synonyms

Meclofenamate
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Endogenous metabolite
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (9)

All WB

Sort by:

Journal Impact Factor

Cancer Commun (Lond)

Helicobacter pylori CagA elevates FTO to induce gastric cancer progression via a "hit-and-run" paradigm. [Abstract]

2025 May;45(5):608-631. PMID: 39960839
Theranostics

Targeting ATF4-dependent pro-survival autophagy to synergize glutaminolysis inhibition. [Abstract]

2021 Jul 25;11(17):8464-8479. PMID: 34373753

Meclofenamic acid purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Jul 25;11(17):8464-8479. [Abstract]

The effect of FTO inhibitor Meclofenamate sodium (MS) (80 μM and 120 μM) on ATF4 protein expression and mTORC1 activity during 968 treatment is detected by western blotting. MS efficiently reduces ATF4 expression and rescues the mTOR downregulation induced by compound 968.
Sensor Actuat B-Chem

2021, 129983.
Biomater Adv

Anti-resorption role of low-intensity pulsed ultrasound (LIPUS) during large-scale bone reconstruction using porous titanium alloy scaffolds through inhibiting osteoclast differentiation. [Abstract]

2023 Nov:154:213634. PMID: 37783002
Biochem Pharmacol

Inhibition of Ca2+-activated chloride channels by the NSAID meclofenamate for anti-diarrhea. [Abstract]

2026 Apr:246:117710. PMID: 41544862
PLoS Pathog

Pseudorabies virus infection triggers pUL46-mediated phosphorylation of connexin-43 and closure of gap junctions to promote intercellular virus spread. [Abstract]

2025 Jan 21;21(1):e1012895. PMID: 39836710
Biomed Opt Express

Investigating tunneling nanotubes in ovarian cancer based on two-photon excitation FLIM-FRET. [Abstract]

2021 Mar 9;12(4):1962-1973. PMID: 33996210
Res Sq

2026 Apr 6.
SSRN

2025 Jan 27.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (337.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Methanol : 7.14 mg/mL (24.11 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3767 mL

16.8833 mL

33.7667 mL

5 mM

0.6753 mL

3.3767 mL

6.7533 mL

10 mM

0.3377 mL

1.6883 mL

3.3767 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Huang Y, et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res. 2015 Jan;43(1):373-84. [Content Brief]

[2]. Conroy MC, et al. Pharmacology, pharmacokinetics, and therapeutic use of meclofenamate sodium. Clin J Pain. 1991;7 Suppl 1:S44-8. [Content Brief]

[3]. Lee YT, et al. Inhibition of hKv2.1, a major human neuronal voltage-gated K+ channel, by meclofenamic acid. Eur J Pharmacol. 1999 Aug 13;378(3):349-56. [Content Brief]

[4]. Eleftheriou CG, et al. Meclofenamic acid improves the signal to noise ratio for visual responses produced by ectopicexpression of human rod opsin. Mol Vis. 2017 Jun 16;23:334-345. eCollection 2017. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Methanol / DMSO	1 mM	3.3767 mL	16.8833 mL	33.7667 mL	84.4167 mL
	5 mM	0.6753 mL	3.3767 mL	6.7533 mL	16.8833 mL
	10 mM	0.3377 mL	1.6883 mL	3.3767 mL	8.4417 mL
	15 mM	0.2251 mL	1.1256 mL	2.2511 mL	5.6278 mL
	20 mM	0.1688 mL	0.8442 mL	1.6883 mL	4.2208 mL
DMSO	25 mM	0.1351 mL	0.6753 mL	1.3507 mL	3.3767 mL
	30 mM	0.1126 mL	0.5628 mL	1.1256 mL	2.8139 mL
	40 mM	0.0844 mL	0.4221 mL	0.8442 mL	2.1104 mL
	50 mM	0.0675 mL	0.3377 mL	0.6753 mL	1.6883 mL
	60 mM	0.0563 mL	0.2814 mL	0.5628 mL	1.4069 mL
	80 mM	0.0422 mL	0.2110 mL	0.4221 mL	1.0552 mL
	100 mM	0.0338 mL	0.1688 mL	0.3377 mL	0.8442 mL

Keywords

Meclofenamic acid

9 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Meclofenamic acid

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Cytoskeleton Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Potassium Channel Compound Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Ion Channel Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Meclofenamic acid

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (9)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Meclofenamic acid Related Classifications

HY-117275 Related Classifications